Double-Blind Crossover Study of Carbuterol and Salbutamol in Bronchial Asthma
Double-Blind Crossover Study of Carbuterol and Salbutamol in Bronchial Asthma
复制标题
卡布特罗和沙丁胺醇治疗支气管哮喘的双盲交叉研究
DOI：
10.1177/030006058100900405
复制
发表时间：
1981
影响因子：
1.6
通讯作者：
G. T. Khemchandani
中科院分区：
文献类型：
--
作者：
N. Misra;U. Tiwari;G. T. Khemchandani
随机选择30例吸入异丙肾上腺素后气道阻塞减轻20%以上的支气管哮喘患者，进行了口服卡布特罗3mg，每日3次，卡布特罗2mg，每日3次和沙丁胺醇4mg的双盲交叉对照研究。每例患者连续接受所有三种药物，每种药物持续6天，中间有一个洗脱期。本研究确定了卡布特罗3 mg每日3次相对优于卡布特罗2 mg和沙丁胺醇4 mg每日3次，表现为主观改善百分比较高（78.8%），更多病例显示偏好（17/27），最少病例需要额外药物（6/27），FEV和MMEFR显著改善（p <0.05）。已知沙丁胺醇会引起心动过速和血压升高。对心血管系统没有不良副作用，但与沙丁胺醇不同的是，carbuterol会使脉搏和血压下降，这应该使carbuterol更容易为患者所接受，特别是在长期使用时。对造血系统和肾脏没有显着的副作用;所有三种类型的治疗中观察到的其他副作用都很小，不需要停药。因此，卡布特罗是一种有效和安全的选择性β-肾上腺素能兴奋剂，相对无副作用，并具有持续的支气管扩张作用，在治疗应用中具有优势，因此是一种治疗支气管哮喘的新的有效药物。
A double-blind crossover comparative study between carbuterol 3 mg thrice daily, carbuterol 2 mg thrice daily and salbutamol 4 mg thrice daily by the oral route was conducted in thirty patients suffering from bronchial asthma, selected at random, with more than 20% reduction in airway obstruction following isoprenaline inhalation. Each patient received all three drugs consecutively, each for 6 days, with a wash-out period in-between. The present study established a relative superiority of carbuterol 3 mg thrice daily over carbuterol 2 mg and salbutamol 4 mg thrice daily as evidenced by a higher percentage of subjective improvement (78.8%), preference shown by more cases (17/27), and need of additional drugs in a minimum number of cases (6/27), and significant improvement in FEV and MMEFR (p < 0.05). Salbutamol is known to produce tachycardia and a rise in blood pressure. There were no adverse side-effects on the cardiovascular system but unlike salbutamol, carbuterol produced a fall in pulse rate and blood pressure which should make carbuterol more acceptable to patients, especially on prolonged usage. There was an absence of significant side-effects on the haemopoietic system and kidneys; other side-effects observed with all three types of treatment were of a minor nature and did not necessitate withdrawal of the drug. Thus, carbuterol is an effective and safe selective beta-adrenergic stimulant, is relatively free from side-effects, and has a sustained bronchodilator effect, an advantage in therapeutic application, and is, as a result, a new effective drug in the management of bronchial asthma.